$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.

2016 Q2 Form 10-Q Financial Statement

#000119312516585837 Filed on May 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.040M $6.100M $2.170M
YoY Change 28.27% 181.11% -29.08%
% of Gross Profit
Research & Development $2.005M $2.408M $2.448M
YoY Change -9.87% -1.65% 111.46%
% of Gross Profit
Depreciation & Amortization $180.0K $3.496K $3.189K
YoY Change 0.0% 9.63% 85.84%
% of Gross Profit
Operating Expenses $5.045M $8.507M $4.620M
YoY Change 9.86% 84.13% 5.43%
Operating Profit -$5.045M -$8.507M -$4.620M
YoY Change 9.87% 84.12% 5.45%
Interest Expense $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0% -104.37%
% of Operating Profit
Other Income/Expense, Net $1.000K $1.000K $95.00K
YoY Change -97.87% -98.95% -104.16%
Pretax Income -$5.040M -$8.510M -$4.530M
YoY Change 11.01% 87.86% -32.08%
Income Tax
% Of Pretax Income
Net Earnings -$5.044M -$8.506M -$4.525M
YoY Change 10.98% 87.98% -32.13%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$23.68K -$41.46K -$24.46K
COMMON SHARES
Basic Shares Outstanding 212.8M shares 205.0M shares 186.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.890M $9.760M $14.17M
YoY Change -78.85% -31.12% -14.89%
Cash & Equivalents $4.891M $9.761M $14.17M
Short-Term Investments
Other Short-Term Assets $316.6K $336.9K $1.224M
YoY Change -73.3% -72.47%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.408M $10.45M $15.86M
YoY Change -77.93% -34.13% -4.73%
LONG-TERM ASSETS
Property, Plant & Equipment $78.15K $81.65K $88.98K
YoY Change -8.91% -8.24% 213.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $27.00K $27.00K $27.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $5.421M $5.571M $6.910M
YoY Change -19.56% -19.38% 66.82%
TOTAL ASSETS
Total Short-Term Assets $5.408M $10.45M $15.86M
Total Long-Term Assets $5.421M $5.571M $6.910M
Total Assets $10.83M $16.02M $22.77M
YoY Change -65.34% -29.65% 9.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $770.0K $1.400M $650.0K
YoY Change 48.08% 115.38% -10.96%
Accrued Expenses $920.0K $440.0K $370.0K
YoY Change 95.74% 18.92% 236.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.689M $1.835M $1.022M
YoY Change 70.84% 79.44% 22.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $50.00K
YoY Change -99.08%
Total Long-Term Liabilities $0.00 $0.00 $50.00K
YoY Change -100.0% -100.0% -99.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.689M $1.835M $1.022M
Total Long-Term Liabilities $0.00 $0.00 $50.00K
Total Liabilities $1.690M $1.830M $1.075M
YoY Change 69.77% 70.24% -82.86%
SHAREHOLDERS EQUITY
Retained Earnings -$194.3M -$189.3M -$160.8M
YoY Change 17.53% 17.71% 5.3%
Common Stock $212.8K $212.8K $186.0K
YoY Change 4.04% 14.44% 7.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.140M $14.18M $21.70M
YoY Change
Total Liabilities & Shareholders Equity $10.83M $16.02M $22.77M
YoY Change -65.34% -29.65% 9.52%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$5.044M -$8.506M -$4.525M
YoY Change 10.98% 87.98% -32.13%
Depreciation, Depletion And Amortization $180.0K $3.496K $3.189K
YoY Change 0.0% 9.63% 85.84%
Cash From Operating Activities -$4.870M -$8.050M -$4.190M
YoY Change 20.84% 92.12% 46.98%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 3.640M 970.0K
YoY Change -100.0% 275.26% -74.5%
NET CHANGE
Cash From Operating Activities -4.870M -8.050M -4.190M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000 3.640M 970.0K
Net Change In Cash -4.870M -4.410M -3.220M
YoY Change -154.47% 36.96% -438.0%
FREE CASH FLOW
Cash From Operating Activities -$4.870M -$8.050M -$4.190M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
59861601 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 pvct Class Of Warrant Or Right Discounted Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightDiscountedExercisePriceOfWarrantsOrRights
0.50
CY2015Q4 pvct Class Of Warrant Or Right Cash Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightCashExercisePriceOfWarrantsOrRights
0.85
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
212829352 shares
CY2013Q2 us-gaap Litigation Reserve
LitigationReserve
100000
CY2016Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7798507 shares
CY2014Q2 us-gaap Loss Contingency Receivable
LossContingencyReceivable
2240000
CY2014Q2 pvct Reimbursement Receivable Percentage
ReimbursementReceivablePercentage
0.25 pure
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14170733
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
212829352 shares
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
212829352 shares
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
312924
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
14184248
CY2016Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1397867
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
123845
CY2016Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
203273872
CY2016Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8970637
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189302453
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16018884
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
212829
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
454524
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1834636
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2016Q1 us-gaap Assets
Assets
16018884
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81649
CY2016Q1 us-gaap Assets Current
AssetsCurrent
10447888
CY2016Q1 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
350000
CY2016Q1 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
683250
CY2016Q1 us-gaap Other Assets Current
OtherAssetsCurrent
336891
CY2016Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2744808
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9760997
CY2016Q1 pvct Litigation Settlement Remaining Balance Due
LitigationSettlementRemainingBalanceDue
2384289
CY2016Q1 pvct Long Term Receivable Reimbursable Legal Fees
LongTermReceivableReimbursableLegalFees
2034289
CY2016Q1 pvct Litigation Settlement Remaining Reserve
LitigationSettlementRemainingReserve
870578
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17391601
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204979100 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
204979100 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
252418
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
16316941
CY2015Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1887171
CY2015Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
1850000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
133282
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
196908112
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8802857
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180796150
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20439812
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
204979
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
451028
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4122871
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Litigation Reserve
LitigationReserve
227750
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2015Q4 us-gaap Assets
Assets
20439812
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
85145
CY2015Q4 us-gaap Assets Current
AssetsCurrent
14720094
CY2015Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
500000
CY2015Q4 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
683250
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
41192
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2912588
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14178902
CY2015Q4 pvct Number Of Shares Issuable On Exercises Of Warrants Issued
NumberOfSharesIssuableOnExercisesOfWarrantsIssued
59861601 shares
CY2015Q4 pvct Litigation Settlement Remaining Balance Due
LitigationSettlementRemainingBalanceDue
2511735
CY2015Q4 pvct Long Term Receivable Reimbursable Legal Fees
LongTermReceivableReimbursableLegalFees
2011735
CY2015Q4 pvct Litigation Settlement Remaining Reserve
LitigationSettlementRemainingReserve
870578
CY2016Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3899254
CY2016Q1 pvct Class Of Warrant Or Right Number Of Warrants Issued During Period
ClassOfWarrantOrRightNumberOfWarrantsIssuedDuringPeriod
7798507 shares
CY2014Q2 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
1120000
CY2014Q2 pvct Annual Cash Bonus Percentage
AnnualCashBonusPercentage
0.70 pure
CY2014Q2 pvct Future Payments Ratio Of Contingent Consideration
FuturePaymentsRatioOfContingentConsideration
2 pure
CY2014Q3 pvct Attorneys Fees Awarded By Court In Legal Settlement
AttorneysFeesAwardedByCourtInLegalSettlement
911000
CY2014Q4 pvct Share Based Compensation Arrangement By Share Based Payment Award Options Settlements In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSettlementsInPeriod
2800000 shares
CY2015 pvct Litigation Settlement Amortization Of Discount
LitigationSettlementAmortizationOfDiscount
103969
CY2015 pvct Litigation Settlement Present Value Of Discount Remaining
LitigationSettlementPresentValueOfDiscountRemaining
197686
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4186816
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
185196323 shares
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-4525107
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4620471
CY2015Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
245668
CY2015Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-266667
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1338
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-94026
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3220868
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
965948
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2448486
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-37082
CY2015Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
211799
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2171985
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1632
CY2015Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167780
CY2015Q1 us-gaap Depreciation
Depreciation
3189
CY2015Q1 pvct Proceeds From Exercises Of Warrants And Stock Options
ProceedsFromExercisesOfWarrantsAndStockOptions
290828
CY2015Q1 pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
94026
CY2015Q1 pvct Net Proceeds From Sales Of Common Stock And Warrants
NetProceedsFromSalesOfCommonStockAndWarrants
675120
CY2015Q1 pvct Issuance Of Stock For Services
IssuanceOfStockForServices
64000
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
3000 shares
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Expired
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsExpired
3693898 shares
CY2015Q1 pvct Interest And Taxes
InterestAndTaxes
0
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8052945
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000315545
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
51745 shares
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
PROVECTUS BIOPHARMACEUTICALS, INC.
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Estimates</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2016Q1 dei Trading Symbol
TradingSymbol
PVCT
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
205278509 shares
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-8506303
CY2016Q1 us-gaap Revenues
Revenues
0
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8507216
CY2016Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
295699
CY2016Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-127446
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
913
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4417905
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3635040
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2407984
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
51069
CY2016Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-489304
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6099232
CY2016Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167780
CY2016Q1 us-gaap Depreciation
Depreciation
3496
CY2016Q1 pvct Litigation Settlement Payment Description
LitigationSettlementPaymentDescription
The remaining cash settlement amounts will continue to be repaid to the Company over a period of four years with the second payment due in total by October 2016 and the final payment is expected to be received by October 3, 2019. $150,000 was repaid by the Executives during the three months ended March 31, 2016. An additional $22,554 of the settlement discount was amortized as of March 31, 2016. $103,969 of the settlement discount was amortized as of December 31, 2015.
CY2016Q1 pvct Issuance Of Stock For Services
IssuanceOfStockForServices
20163
CY2016Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Expired
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsExpired
1048494 shares
CY2016Q1 pvct Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3635040
CY2016Q1 pvct Litigation Settlement Amortization Of Discount
LitigationSettlementAmortizationOfDiscount
22554
CY2016Q1 pvct Litigation Settlement Present Value Of Discount Remaining
LitigationSettlementPresentValueOfDiscountRemaining
175132
CY2016Q1 pvct Increase Decrease In Accrued Settlement Expenses
IncreaseDecreaseInAccruedSettlementExpenses
-1850000
CY2016Q1 pvct Warrant Incentive Expense
WarrantIncentiveExpense
2718407
CY2016Q1 pvct Interest And Taxes
InterestAndTaxes
0
CY2016Q1 pvct Independent Contractor Agreement Term Description
IndependentContractorAgreementTermDescription
The initial term of the independent contractor agreement is from April 19, 2016 to December 1, 2016, and thereafter will continue on a month to month basis unless terminated by either party upon 30 days prior written notice.

Files In Submission

Name View Source Status
0001193125-16-585837-index-headers.html Edgar Link pending
0001193125-16-585837-index.html Edgar Link pending
0001193125-16-585837.txt Edgar Link pending
0001193125-16-585837-xbrl.zip Edgar Link pending
d145017d10q.htm Edgar Link pending
d145017dex311.htm Edgar Link pending
d145017dex312.htm Edgar Link pending
d145017dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pvct-20160331.xml Edgar Link completed
pvct-20160331.xsd Edgar Link pending
pvct-20160331_cal.xml Edgar Link unprocessable
pvct-20160331_def.xml Edgar Link unprocessable
pvct-20160331_lab.xml Edgar Link unprocessable
pvct-20160331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending